Michael P Manns

Summary

Affiliation: Hannover Medical School
Country: Germany

Publications

  1. doi request reprint Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial
    Michael Manns
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Antivir Ther 16:1021-33. 2011
  2. ncbi request reprint Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
    Michael Manns
    Medizinische Hochschule Hannover, Department of Gastroenterology, Hepatology and Endocrinology, Hannover, Germany Electronic address
    Lancet 384:414-26. 2014
  3. ncbi request reprint The Combination of MK-5172, Peginterferon, and Ribavirin Is Effective in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection Without Cirrhosis
    Michael P Manns
    Hannover Medical School, Hannover, Germany German Center for Infection research DZIF, Hannover Braunschweig, Germany Electronic address
    Gastroenterology 147:366-376.e6. 2014
  4. doi request reprint Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin
    M P Manns
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    J Viral Hepat 20:524-9. 2013
  5. ncbi request reprint Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study
    Michael P Manns
    Department of Gastroenterology, Hepatology, and Endocrinology, Medical School of Hannover, Hannover, Germany
    Hepatology 56:884-93. 2012
  6. pmc Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks
    M P Manns
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    J Viral Hepat 19:537-46. 2012
  7. ncbi request reprint Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901
    Michael P Manns
    Medical School of Hannover, Department of Gastroenterology, Hepatology and Endocrinology, Carl Neuberg Str 1, 30625 Hannover, Germany
    Expert Opin Drug Saf 11:361-8. 2012
  8. doi request reprint Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1
    Michael P Manns
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Liver Int 32:27-31. 2012
  9. pmc Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response
    Manuela F Meyer
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Virol J 4:58. 2007
  10. pmc Plasma bile acids are not associated with energy metabolism in humans
    Gemma Brufau
    Dept, of Pediatrics, Center for Liver, Digestive and Metabolic Diseases, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands
    Nutr Metab (Lond) 7:73. 2010

Collaborators

Detail Information

Publications185 found, 100 shown here

  1. doi request reprint Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial
    Michael Manns
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Antivir Ther 16:1021-33. 2011
    ..Antiviral activity of TMC435, an oral, once-daily, HCV NS3/4A protease inhibitor, was evaluated with pegylated interferon-α2a/ribavirin (P/R) in HCV genotype-1 patients...
  2. ncbi request reprint Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
    Michael Manns
    Medizinische Hochschule Hannover, Department of Gastroenterology, Hepatology and Endocrinology, Hannover, Germany Electronic address
    Lancet 384:414-26. 2014
    ....
  3. ncbi request reprint The Combination of MK-5172, Peginterferon, and Ribavirin Is Effective in Treatment-Naive Patients With Hepatitis C Virus Genotype 1 Infection Without Cirrhosis
    Michael P Manns
    Hannover Medical School, Hannover, Germany German Center for Infection research DZIF, Hannover Braunschweig, Germany Electronic address
    Gastroenterology 147:366-376.e6. 2014
    ..We investigated the efficacy and tolerability of MK-5172 with peginterferon and ribavirin (PR) in treatment-naive patients with chronic HCV genotype 1 infection without cirrhosis...
  4. doi request reprint Long-term clearance of hepatitis C virus following interferon α-2b or peginterferon α-2b, alone or in combination with ribavirin
    M P Manns
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    J Viral Hepat 20:524-9. 2013
    ..1-99.7%] for IFN α-2b and 99.4% (95% CI, 97.7-99.9%) for PEG-IFN α-2b. Successful treatment of hepatitis C with PEG-IFN α-2b or IFN α-2b leads to clinical cure of hepatitis C in the vast majority of cases...
  5. ncbi request reprint Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study
    Michael P Manns
    Department of Gastroenterology, Hepatology, and Endocrinology, Medical School of Hannover, Hannover, Germany
    Hepatology 56:884-93. 2012
    ..The incidence of adverse events was generally comparable between vaniprevir and placebo recipients; however, vomiting appeared to be more common at higher vaniprevir doses...
  6. pmc Glycyrrhizin in patients who failed previous interferon alpha-based therapies: biochemical and histological effects after 52 weeks
    M P Manns
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    J Viral Hepat 19:537-46. 2012
    ..Generally, glycyrrhizin treatment was well tolerated...
  7. ncbi request reprint Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901
    Michael P Manns
    Medical School of Hannover, Department of Gastroenterology, Hepatology and Endocrinology, Carl Neuberg Str 1, 30625 Hannover, Germany
    Expert Opin Drug Saf 11:361-8. 2012
    ..To review long-term safety data from the rollover study ETV-901, focusing on adverse events (AEs) with a potential nucleos(t)ide association...
  8. doi request reprint Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1
    Michael P Manns
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Liver Int 32:27-31. 2012
    ..This review summarizes the results of SPRINT-2, a phase III double blind, placebo controlled study in which the efficacy and safety of Boceprevir, a new HCV protease inhibitor, was compared to SOC...
  9. pmc Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response
    Manuela F Meyer
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Virol J 4:58. 2007
    ..Thus, these cases highlight that clearance of low levels of HCV viremia is possible in the absence of a strong adaptive immune response which might explain the low seroconversion rate after occupational exposure to HCV...
  10. pmc Plasma bile acids are not associated with energy metabolism in humans
    Gemma Brufau
    Dept, of Pediatrics, Center for Liver, Digestive and Metabolic Diseases, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands
    Nutr Metab (Lond) 7:73. 2010
    ..Therefore, our data do not support an important role of circulating BA in the control of human energy metabolism...
  11. pmc Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study
    Anne Hafer
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Carl Neuberg Str 1, 30625 Hannover, Germany
    BMC Gastroenterol 7:36. 2007
    ..The aim of the present study was to investigate the clinical and histological efficacy of lactulose in patients with inflammatory bowel disease (IBD), for which probiotic therapy yielded promising results...
  12. pmc cAMP-dependent and cholinergic regulation of the electrogenic intestinal/pancreatic Na+/HCO3- cotransporter pNBC1 in human embryonic kidney (HEK293) cells
    Oliver Bachmann
    Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover, Germany
    BMC Cell Biol 9:70. 2008
    ..After having shown activation of NBC by carbachol and forskolin in murine colon, we now investigated these pathways in HEK293 cells transiently expressing a GFP-tagged pNBC1 construct...
  13. pmc A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma
    Tim F Greten
    Department of Gastroenterology, Hannover Medical School, Carl Neuberg Strasse 1, 30625 Hannover, Germany
    BMC Cancer 10:209. 2010
    ..In this open label, single arm clinical trial, we analyzed the effect of a low dose cyclophosphamide treatment in combination with a telomerase peptide (GV1001) vaccination in patients with advanced HCC...
  14. doi request reprint Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis
    Michael P Manns
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Gastroenterology 139:1198-206. 2010
    ..We compared the effects of budesonide (a steroid that is rapidly metabolized, with low systemic exposure) and prednisone, both in combination with azathioprine...
  15. ncbi request reprint Current state of interferon therapy in the treatment of chronic hepatitis B
    Michael P Manns
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Hannover, Germany
    Semin Liver Dis 22:7-13. 2002
    ..For most patients with chronic hepatitis B, including those infected neonatally and those with HBeAg-negative disease, safe, tolerable, and effective alternatives to IFN are needed...
  16. ncbi request reprint [Autoimmune hepatitis]
    M P Manns
    Abteilung für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover
    Z Gastroenterol 40:39-42. 2002
  17. ncbi request reprint Minilaparoscopy for early diagnosis of cirrhosis: is the endoscopist's eye better than the histopathologist's?
    M P Manns
    Dept of Gastroenterology, Hepatology, and Endocrinology, Medical School of Hanover, Carl Neuberg Strasse 1, 30623 Hanover, Germany
    Endoscopy 35:74-5. 2003
  18. pmc Treating viral hepatitis C: efficacy, side effects, and complications
    M P Manns
    Department of Gastroenterology, Hepatology, and Endocrinology, Medical School of Hannover, Carl Neuberg Str 1, D 30625 Hannover, Germany
    Gut 55:1350-9. 2006
    ..This review describes the efficacy and optimisation of the current standard therapy of hepatitis C and its problems in special patient populations. New treatment directions beyond interferon alpha based therapies are on the horizon...
  19. ncbi request reprint Autoimmune hepatitis, from mechanisms to therapy
    Michael P Manns
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Germany
    Hepatology 43:S132-44. 2006
    ..Given the importance of serological testing, the IAHG is also working on guidelines and procedures for more reliable and standardized testing of autoantibodies...
  20. ncbi request reprint The way forward in HCV treatment--finding the right path
    Michael P Manns
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Hannover, Germany
    Nat Rev Drug Discov 6:991-1000. 2007
    ..Here we review the specific challenges posed by HCV, and recent developments in the design of vaccines and novel antiviral agents...
  21. ncbi request reprint [Standard treatment of chronic hepatitis B]
    M P Manns
    Medizinische Hochschule Hannover, Abt Gastroenterologie, Hepatologie und Endokrinologie, Hannover
    Z Gastroenterol 42:687-91. 2004
  22. ncbi request reprint Adherence to combination therapy: influence on sustained virologic response and economic impact
    Michael P Manns
    Department of Gastroenterology, Hepatology, and Endocrinology, Medizinische Hochschule Hannover, Carl Neuberg Strasse 1, D 30625 Hannover, Germany
    Gastroenterol Clin North Am 33:S11-24. 2004
    ..Further research will be needed to develop optimum and cost-effective treatment strategies for the general HCV-infected population, particularly patients with comorbidities...
  23. ncbi request reprint [Diagnosis, progression and therapy of hepatitis-B-virus infection--results of an evidenced based consensus conference of the German Society for Alimentary Metabolic Disorders and and in cooperation with the Hepatitis Competence Network]
    M P Manns
    Medizinische Hochschule Hannover, Abt Gastroenterologie, Hepatologie und Endokrinologie, Hannover
    Z Gastroenterol 42:677-8. 2004
  24. doi request reprint Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C
    Michael Manns
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    J Hepatol 55:554-63. 2011
    ..There is increasing interest in identifying patients with chronic hepatitis C genotype 2 or 3 infection in whom it is possible to lower the burden of therapy while retaining high levels of efficacy...
  25. doi request reprint Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection
    Michael P Manns
    Hannover Medical School, Department of Gastroenterology, Hepatology, and Endocrinology, Center for Internal Medicine, Hannover, Germany
    J Hepatol 54:1114-22. 2011
    ..BI201335 is a highly specific and potent HCV protease inhibitor. This multiple rising dose trial evaluated antiviral activity and safety in chronic HCV genotype-1 patients...
  26. ncbi request reprint Current and future treatment of hepatitis C
    M P Manns
    Department of Gastroenterology and Hepatology, Medizinische Hochschule Hannover, Hannover, Germany
    Indian J Gastroenterol 20:C47-51. 2001
    ..Hopefully, new treatment modalities will be available in the near future. Helicase, protease and the RNA polymerase are potential targets to suppress HCV replication and several immunotherapeutic approaches are explored...
  27. ncbi request reprint Famciclovir treatment of hepatitis B infection following liver transplantation: a long-term, multi-centre study
    M P Manns
    Department of Gastroenterology and Hepatology, Center for Internal Medicine, Medical School of Hannover, Hannover, Germany
    Transpl Infect Dis 3:16-23. 2001
    ..Famciclovir therapy was safe and well tolerated; serious adverse events were reported infrequently. Famciclovir treatment may be beneficial in patients with hepatitis B infection post-OLT...
  28. ncbi request reprint Republished paper: Managing HBV in patients with impaired immunity
    Karsten Wursthorn
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl Neuberg Str 1, D 30625 Hannover, Germany
    Postgrad Med J 87:223-38. 2011
    ..This review will summarise the current knowledge on pathogenesis, frequency and treatment options of HBV reactivations in patients with impaired immunity...
  29. ncbi request reprint Autoimmunity and extrahepatic manifestations in hepatitis C virus infection
    M P Manns
    Dept of Gastroenterology and Hepatology, Medizinische Hochschule Hannover, Germany
    J Hepatol 31:39-42. 1999
    ..If there is any evidence of an aetiological association of replicative hepatitis C infection and the above-mentioned extrahepatic diseases, antiviral treatment should be considered...
  30. ncbi request reprint Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial
    M P Manns
    Division of Gastroenterology and Hepatology, Medical School of Hannover, Hannover, Germany
    Lancet 358:958-65. 2001
    ..In this randomised trial, peginterferon alfa-2b plus ribavirin was compared with interferon alfa-2b plus ribavirin...
  31. ncbi request reprint Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma
    Bita Boozari
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Carl Neuberg Strasse 1, 25 Hannover, Germany
    Gut 59:1416-26. 2010
    ....
  32. doi request reprint Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection
    Kerstin A Stegmann
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Gastroenterology 138:1885-97. 2010
    ..Natural killer (NK) cells might be associated with control of HCV infection. We examined the effects of IFNalpha on human NK cells and its relevance to HCV infection...
  33. ncbi request reprint Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective
    Jerzy Jaroszewicz
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl Neuberg Str 1, Hannover, Germany
    J Hepatol 52:514-22. 2010
    ..However, there is limited information on HBsAg levels considering the dynamic natural course of HBV-infection. This study aimed to determine HBsAg levels in the different phases of HBV-infection in European HBsAg-positive patients...
  34. pmc Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma
    Fei Zhao
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany
    Immunology 128:141-9. 2009
    ..These results highlight the importance of blocking these suppressor mechanisms early in the disease in developing immunotherapy protocols...
  35. ncbi request reprint Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection
    Xandra Volkmann
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Hepatology 43:1311-6. 2006
    ..845; 95% CI). In conclusion, hepatic caspase activity might play a role in HCV clearance and could also predict the efficacy of antiviral therapy...
  36. ncbi request reprint Aryl hydrocarbon receptor-mediated regulation of the human estrogen and bile acid UDP-glucuronosyltransferase 1A3 gene
    Tim O Lankisch
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl Neuberg Strasse 1, Hannover, Germany
    Arch Toxicol 82:573-82. 2008
    ..UGT1A3 transcription was reduced in the presence of promoter SNPs. These data demonstrate xenobiotic induced regulation of the UGT1A3 gene by the AhR, which shows genetic variability...
  37. ncbi request reprint Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases
    Konrad L Streetz
    Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany
    Hepatology 38:218-29. 2003
    ..Hepatology 2003;38:218-229)...
  38. ncbi request reprint Fate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha2b therapy for acute hepatitis C
    Johannes Wiegand
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Germany
    Antivir Ther 12:303-16. 2007
    ..However, recent studies described a decline in HCV-specific CD8+ T-cells during interferon treatment, suggesting that the success of acute HCV therapy might be independent of adaptive immunity...
  39. ncbi request reprint Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma
    Lars A Ormandy
    Department of Gastroenterology, Hepatology und Endocrinology, Medizinische Hochschule Hannover, Carl Neuberg Str 1, 30625 Hannover, Germany
    World J Gastroenterol 12:3275-82. 2006
    ..To analyze the phenotype and function of dendritic cells (DC) from patients with hepatocellular carcinoma (HCC) in order to understand their role in this disease...
  40. ncbi request reprint Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons
    Dominik Jarczak
    Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Germany
    FEBS J 272:5910-22. 2005
    ....
  41. pmc Secretagogue stimulation enhances NBCe1 (electrogenic Na(+)/HCO(3)(-) cotransporter) surface expression in murine colonic crypts
    Haoyang Yu
    Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Germany
    Am J Physiol Gastrointest Liver Physiol 297:G1223-31. 2009
    ..Taken together, our results demonstrate a secretagogue-induced increase of NBCe1 membrane expression. Vesicle traffic and exocytosis might thus represent a novel mechanism of intestinal NBC activation by secretagogues...
  42. pmc The strength of the Fas ligand signal determines whether hepatocytes act as type 1 or type 2 cells in murine livers
    Sven Schüngel
    Clinic of Hepatology, Gastroenterology and Endocrinology, Hannover Medical School, Hannover, Germany
    Hepatology 50:1558-66. 2009
    ..In contrast to previous in vitro findings, phosphorylation of Bid does not affect the sensitivity of hepatocytes to Fas receptor-mediated apoptosis in vivo...
  43. doi request reprint Peginterferon plus adefovir versus either drug alone for hepatitis delta
    Heiner Wedemeyer
    Hannover Medical School, Hannover, Germany
    N Engl J Med 364:322-31. 2011
    ..There is no currently approved treatment. We investigated the safety and efficacy of 48 weeks of treatment with peginterferon alfa-2a plus adefovir dipivoxil, peginterferon alfa-2a alone, and adefovir dipivoxil alone...
  44. pmc The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury
    Christian Klein
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    J Clin Invest 115:860-9. 2005
    ..Additionally, we identified the IL-6-gp130-STAT3-dependent proteins KC and SAA2 as new candidates for therapeutic targets in liver diseases...
  45. ncbi request reprint Quantitative gene expression profiling reveals a fetal hepatic phenotype of murine ES-derived hepatocytes
    Andrea Jochheim
    Hannover Medical School, Center of Internal Medicine, Department of Gastroenterology, Hepatology and Endocrinology, Hannover, Germany
    Int J Dev Biol 48:23-9. 2004
    ..With sophisticated differentiation protocols, hepatic gene expression can be induced in a proportion of ES cells with gene expression patterns similar to early fetal liver...
  46. ncbi request reprint Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA
    Christian Klein
    Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Germany
    Gastroenterology 125:9-18. 2003
    ..Animal models to study new treatment options in vivo have several drawbacks. Therefore, we were interested to establish a new small animal model in which HBV replication and especially new treatment options can be studied easily...
  47. doi request reprint Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation
    Nazanin Hooman
    Department of Gastroenterology, Medizinische Hochschule Hannover, Hannover, Germany
    Liver Transpl 14:435-42. 2008
    ..That is, IM HBIG is not dose-saving; however, it may be cost-effective if the price per unit is lower. Individualized dosing intervals should be further evaluated as a cost-effective alternative to fixed dosing schemes...
  48. doi request reprint Natural history: the importance of viral load, liver damage and HCC
    Karsten Wursthorn
    Clinic for Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Best Pract Res Clin Gastroenterol 22:1063-79. 2008
    ..In addition to the better-known factors- including coinfections with HBV and HIV- progression of liver disease is adversely affected by smoking, hepatic steatosis and insulin resistance...
  49. doi request reprint Gilbert's syndrome and hyperbilirubinemia in protease inhibitor therapy--an extended haplotype of genetic variants increases risk in indinavir treatment
    Tim O Lankisch
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl Neuberg Str 1, 30625 Hannover, Germany
    J Hepatol 50:1010-8. 2009
    ..Indinavir (IDV) can lead to hyperbilirubinemia in Gilbert's syndrome (UGT1A1*28), which does not explain interindividual severity differences and may thus involve additional UGT1A variants...
  50. ncbi request reprint Lack of gp130 expression in hepatocytes promotes liver injury
    Konrad L Streetz
    Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany
    Gastroenterology 125:532-43. 2003
    ..To define the IL-6-dependent intracellular pathways more specifically, we generated a hepatocyte-specific gp130 knockout mouse...
  51. ncbi request reprint Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma
    Arne Dettmer
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Germany
    World J Gastroenterol 12:3707-15. 2006
    ....
  52. doi request reprint Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatment
    Ingmar Mederacke
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Antivir Ther 17:305-12. 2012
    ..We performed anti-HDV IgM testing in a well defined cohort of HDV-infected patients who were treated with pegylated interferon-α2a plus adefovir, or either drug alone...
  53. ncbi request reprint IL-4-induced priming of human intestinal mast cells for enhanced survival and Th2 cytokine generation is reversible and associated with increased activity of ERK1/2 and c-Fos
    Axel Lorentz
    Department of Gastroenterology, Hepatology, and Endocrinology, Medical School of Hannover, Germany
    J Immunol 174:6751-6. 2005
    ..In summary, our data show that the IL-4 effects on human intestinal mast cell functions are reversible and accompanied by an increased activity of ERK1/2 and c-Fos...
  54. doi request reprint Coffee induces expression of glucuronosyltransferases by the aryl hydrocarbon receptor and Nrf2 in liver and stomach
    Sandra Kalthoff
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Gastroenterology 139:1699-710, 1710.e1-2. 2010
    ..UDP glucuronosyltransferases (UGT1A) are proteins with indirect antioxidant, cytoprotective, and genoprotective capabilities; we examined UGT1A regulation in response to coffee in cultured cells and mice...
  55. ncbi request reprint A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels
    Johannes Wiegand
    Abteilung Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Germany
    Antivir Ther 13:547-54. 2008
    ..As quantitative assays for HBsAg recently became available, we have investigated whether quantitative HBsAg measurements can substitute for hepatitis B virus (HBV) DNA quantification in treatment monitoring...
  56. ncbi request reprint Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient
    Andrej Potthoff
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Eur J Gastroenterol Hepatol 19:906-9. 2007
    ..Monitoring of HBsAg levels can be useful in individualizing optimal treatment duration in HBV-infected patients...
  57. ncbi request reprint CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice
    Lydia A Haile
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Germany
    J Immunol 185:203-10. 2010
    ..We suggest that CD49d can be used as an alternative marker for Gr-1 to differentiate between the subpopulations of MDSCs together with CD11b, which will ultimately help in understanding the mechanisms of immune suppression by MDSCs...
  58. ncbi request reprint Gilbert's syndrome and antiviral therapy of hepatitis C
    Katja Deterding
    Dept of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Ann Hepatol 8:246-50. 2009
    ..Of note, both patients recovered from their initial unconjugated hyperbilirubinemia despite continuation of ribavirin therapy, which indicates that compensatory mechanisms leading to a normalization of UGT1A1 activity are likely...
  59. doi request reprint Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial
    Katja Deterding
    Hep Net German Network of Competence on Viral Hepatitis, Hannover, Germany
    Lancet Infect Dis 13:497-506. 2013
    ..We aimed to assess an alternative treatment strategy of delayed antiviral therapy in patients who do not eliminate the virus spontaneously compared with immediate treatment...
  60. doi request reprint Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum
    Karsten Wursthorn
    Dept of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl Neuberg Str 1, 30625 Hannover, Germany
    J Clin Virol 50:292-6. 2011
    ..Studies have shown that serum HBsAg quantification during, and at end of, treatment may predict long-term HBsAg loss...
  61. doi request reprint Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients
    Karsten Wursthorn
    Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover, Germany
    Hepatology 52:1611-20. 2010
    ..In patients with subsequent HBsAg loss, viral antigens were already undetectable in liver biopsy samples after 1 year of treatment. This was associated with markedly enhanced antiviral T cell reactivity...
  62. doi request reprint HCV core antigen testing in HIV- and HBV-coinfected patients, and in HCV-infected patients on hemodialysis
    Ingmar Mederacke
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl Neuberg Str 1, D 30625 Hannover, Germany
    J Clin Virol 53:110-5. 2012
    ..A quantitative HCV core antigen (HCVcoreAg) immunoassay has been developed for the confirmation of viremia in patients with hepatitis C...
  63. doi request reprint Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment
    Jan Grabowski
    Hannover Medical School, Department of Gastroenterology, Hepatology and Endocrinology, Hannover, Germany
    Liver Int 31:1395-405. 2011
    ..The role of the adaptive immune system in controlling HDV infection during spontaneous or treatment-induced viral clearance is not well understood...
  64. ncbi request reprint Interferon-alpha enhances TRAIL-mediated apoptosis by up-regulating caspase-8 transcription in human hepatoma cells
    Christian Liedtke
    Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Carl Neuberg Strasse 1, D 30625 Hannover, Germany
    J Hepatol 44:342-9. 2006
    ..The exact mechanisms underlying the antiviral and antitumor effects of IFNalpha are not completely understood. In this study, we investigated if the pro-apoptotic factor caspase-8 is a target gene of IFNalpha signalling...
  65. doi request reprint Glucocorticosteroids increase cell entry by hepatitis C virus
    Sandra Ciesek
    Department of Gastroenterology, Hepatology, and Endocrinology, Hannover Medical School, Hannover, Germany
    Gastroenterology 138:1875-84. 2010
    ..However, these drugs worsen hepatitis C virus (HCV) recurrence after liver transplantation, suggesting that they may directly exacerbate HCV infection...
  66. ncbi request reprint Rapamycin delays tumor development in murine livers by inhibiting proliferation of hepatocytes with DNA damage
    Laura Elisa Buitrago-Molina
    Clinic of Hepatology, Gastroenterology, and Endocrinology, Hannover Medical School, Hannover, Germany
    Hepatology 50:500-9. 2009
    ..Furthermore, RAD001 sustains the apoptosis sensitivity of hepatocytes during chronic liver injury by inhibiting p53-induced p21 expression. Long-term treatment with RAD001 markedly delays DNA damage-induced liver tumor development...
  67. doi request reprint Prognostic implications of lactate, bilirubin, and etiology in German patients with acute liver failure
    Johannes Hadem
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Clin Gastroenterol Hepatol 6:339-45. 2008
    ..The accuracy of these parameters in predicting transplantation or death shows significant variation in different countries...
  68. doi request reprint Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway
    Lydia A Haile
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany
    Gastroenterology 135:871-81, 881.e1-5. 2008
    ..Here, for the first time, we have identified and analyzed their role in inflammatory bowel disease (IBD)...
  69. ncbi request reprint Activation of nuclear factor E2-related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development
    Silke Marhenke
    Department of Hepatology, Medical School Hannover, Hannover, Germany
    Hepatology 48:487-96. 2008
    ..Our data establish a central role for Nrf2 in the protection against Faa-induced liver injury; the Nrf2 regulated cellular defense not only prevents acute Faa-induced liver failure but also delays hepatocarcinogenesis in HT1...
  70. pmc The cyclin E regulator cullin 3 prevents mouse hepatic progenitor cells from becoming tumor-initiating cells
    Uta Kossatz
    Institute for Molecular Biology, Hannover Medical School, Hannover, Germany
    J Clin Invest 120:3820-33. 2010
    ..The expression of Cul3 during hepatic differentiation therefore safeguards against the formation of progenitor cells that carry a great potential for transformation into tumor-initiating cells...
  71. ncbi request reprint Genetic variability of aryl hydrocarbon receptor (AhR)-mediated regulation of the human UDP glucuronosyltransferase (UGT) 1A4 gene
    Thomas J Erichsen
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover, Medical School, Hannover, Germany
    Toxicol Appl Pharmacol 230:252-60. 2008
    ..AhR-mediated regulation of the human UGT1A4 gene by two XRE and a modulation by naturally occurring genetic variability by SNPs is demonstrated, which indicates gene-environment interaction with potential relevance for drug metabolism...
  72. pmc Targeting of p53-transcriptional dysfunction by conditionally replicating adenovirus is not limited by p53-homologues
    Florian Kuhnel
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany
    Mol Ther 18:936-46. 2010
    ..Moreover, Adp53sensor provides a strategy that should be applicable to other transcriptionally regulated DNA viruses...
  73. pmc Selectivity of oncolytic viral replication prevents antiviral immune response and toxicity, but does not improve antitumoral immunity
    Engin Gürlevik
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany
    Mol Ther 18:1972-82. 2010
    ..In summary, the degree of tumor selectivity of viral replication marginally influences antitumoral immune responses, but is a major determinant of antivector immunity and systemic toxicity...
  74. doi request reprint Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours
    Stefan Heringlake
    Department of Gastroenterology, Ruhr University Bochum, Knappschaftskrankenhaus, In der Schornau 23 25, Bochum, Germany
    J Hepatol 52:220-7. 2010
    ..The aim of our study was to search for highly up-regulated genes in primary malignant liver tumours and to analyse their expression at the mRNA- and protein level...
  75. doi request reprint Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses
    Ramakrishna Edukulla
    Department of Gastroenterology, Medical School Hannover, Hannover, Germany
    Cancer Res 69:1448-58. 2009
    ....
  76. ncbi request reprint Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma
    Firouzeh Korangy
    Department of Gastroenterology, Hepatology and Endocrinology, Clinic of Visceral and Transplantation Surgery, Medizinische Hochschule Hannover, Hannover, Germany
    Clin Cancer Res 10:4332-41. 2004
    ..NY-ESO-1, a member of the cancer testis antigen family, is one possible candidate for a tumor-specific antigen in HCC. The aim of this study was to show the relevance of NY-ESO-1 in hepatocellular carcinoma...
  77. ncbi request reprint Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation
    Jens Rosenau
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Liver Transpl 13:367-73. 2007
    ..Further studies should address the question, of whether the use of potent adjuvant systems results in higher response rates...
  78. ncbi request reprint Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis
    Ralf Lichtinghagen
    Department of Clinical Chemistry, Medizinische Hochschule Hannover, Carl Neuberg Str 1, D 30623 Hannover, Germany
    Clin Sci (Lond) 105:373-82. 2003
    ..In conclusion, MMP expression during the course of chronic hepatitis C appears to be a closely regulated process, with different clusters of coordinately regulated MMP genes being identified...
  79. doi request reprint Nuclear factor-eythroid 2-related factor 2 prevents alcohol-induced fulminant liver injury
    Jutta Lamlé
    Department of Hepatology, Gastroenterology and Endocrinology, Hannover, Germany
    Gastroenterology 134:1159-68. 2008
    ..Increased oxidative stress has been implicated in the pathophysiology of many diseases including ethanol-induced liver disease. Therefore, the role of Nrf2(-/-) in ethanol-induced liver injury was investigated...
  80. ncbi request reprint Family 1 uridine-5'-diphosphate glucuronosyltransferases (UGT1A): from Gilbert's syndrome to genetic organization and variability
    Christian P Strassburg
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl Neuberg Str 1, 30625 Hannover, Germany
    Arch Toxicol 82:415-33. 2008
    ..Glucuronidation and its variability are likely to represent an important factor for individualized drug therapy and risk prediction impacting the drug development and licensing processes...
  81. pmc Rapid allelic discrimination by TaqMan PCR for the detection of the Gilbert's syndrome marker UGT1A1*28
    Ursula Ehmer
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl Neuberg Str 1, 30625 Hannover, Germany
    J Mol Diagn 10:549-52. 2008
    ..The method utilizes a technological platform that is widely used in clinical practice and could therefore be easily adapted for routine clinical applications...
  82. ncbi request reprint ME3738 protects from concanavalin A-induced liver failure via an IL-6-dependent mechanism
    Christian Klein
    Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany
    Eur J Immunol 33:2251-61. 2003
    ..Therefore, we demonstrate that ME3738 triggers IL-6 expression, which activates pathways that are relevant to protect from Con A-induced liver failure...
  83. pmc Identification of a novel murine pancreatic tumour antigen, which elicits antibody responses in patients with pancreatic carcinoma
    Fei Zhao
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany
    Immunology 128:134-40. 2009
    ..Reverse transcriptase-polymerase chain reaction analysis showed Tankyrase-2 expression in human pancreatic tumour. These findings show the relevance of spontaneous murine tumour models for the identification of human tumour antigens...
  84. ncbi request reprint Prophylaxis, diagnosis and therapy of hepatitis B virus (HBV) infection: the German guidelines for the management of HBV infection
    M Cornberg
    Abteilung Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover
    Z Gastroenterol 45:1281-328. 2007
  85. ncbi request reprint Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin
    A Potthoff
    Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany
    Scand J Gastroenterol 44:1487-90. 2009
    ..In contrast, a sustained response concerning HCV is durable. We recommend long-term monitoring of HBV/HCV-co-infected patients after IFN a-based therapies...
  86. ncbi request reprint Interleukin-6/glycoprotein 130-dependent pathways are protective during liver regeneration
    Torsten Wuestefeld
    Department of Gastroenterology, Hepatology, and Endocrinology, Medizinische Hochschule Hannover, 30625 Hannover, Germany
    J Biol Chem 278:11281-8. 2003
    ..Thus our results suggest that the role of gp130-dependent signaling is not a direct influence on cell cycle progression after partial hepatectomy but is to activate protective pathways important to enable hepatocyte proliferation...
  87. ncbi request reprint Treatment of chronic hepatitis C with PEGylated interferon and ribavirin
    Markus Cornberg
    Department of Gastroenterology, Hepatology, and Endocrinology, Medical School Hannover, Carl Neuberg Strasse 1, D 30623 Hannover, Germany
    Curr Gastroenterol Rep 4:23-30. 2002
    ..This review describes recent advances in the treatment of HCV infection with PEGylated interferon (interferon modified with polyethylene glycol [PEG] ) combined with ribavirin...
  88. ncbi request reprint Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C
    Markus Cornberg
    Department of Gastroenterology, Hepatology, and Endocrinology, Medizinische Hochschule Hannover, Carl Neuberg Strasse 1, D 30625 Hannover, Germany
    J Hepatol 37:843-7. 2002
    ..The present study is a pilot study evaluating the efficacy and safety of combination therapy with interferon alfa-2a and MMF in interferon alfa nonresponder patients...
  89. ncbi request reprint Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study
    Markus Cornberg
    Abt Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Germany
    J Hepatol 44:291-301. 2006
    ..Therapeutic options for hepatitis C non-responder patients are limited...
  90. ncbi request reprint Hepatitis C: therapeutic perspectives
    M Cornberg
    Department of Gastroenterology and Hepatology, Medical School Hannover, Germany
    Forum (Genova) 11:154-62. 2001
    ..Finally, immunotherapies to enhance HCV-specific immune responses are also attractive strategies to control HCV infection and to prevent chronic liver disease...
  91. ncbi request reprint Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated
    J Wiegand
    Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany
    Z Gastroenterol 42:15-8. 2004
    ..The recently FDA approved nucleoside analogue adefovir dipivoxil has potent antiviral activity against lamivudine-resistant mutants and can prevent viral replication effectively...
  92. ncbi request reprint Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay
    P Fytili
    Medizinische Hochschule Hannover, Abteilung für Gastroenterologie, Hepatologie und Endokrinologie, Carl Neuberg Str 1, 30625 Hannover, Germany
    J Clin Virol 39:308-11. 2007
    ..Only limited data is available on the frequency and clinical significance of very low hepatitis C viremia (<600 IU/ml) determined by novel sensitive methods for HCV quantification...
  93. doi request reprint Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab
    M A Stange
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany
    Z Gastroenterol 48:258-63. 2010
    ..Pre-emptive antiviral treatments should be administered since delayed antiviral treatment is frequently unable to prevent liver failure...
  94. ncbi request reprint Viral hepatitis after liver transplantation. Which immunosuppressive drugs should be recommended?
    S Ciesek
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Minerva Gastroenterol Dietol 53:337-50. 2007
    ..Further trials are urgently needed to clarify the role of different immunosuppressive compounds in hepatitis C after transplantation...
  95. ncbi request reprint Polyethylene glycol-interferon: current status in hepatitis C virus therapy
    Heiner Wedemeyer
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    J Gastroenterol Hepatol 17:S344-50. 2002
    ..The combination of PEG-interferon and ribavirin improves the overall sustained response rates to 54-56% and represents the new standard therapy for patients with chronic hepatitis C infection in most patients...
  96. doi request reprint Treatment of HBV/HCV coinfection
    Andrej Potthoff
    Hannover Medical School, Medizinische Hochschule Hannover, Department of Gastroenterology, Hepatology and Endocrinology, Carl Neuberg Str 1, D 30625 Hannover, Germany
    Expert Opin Pharmacother 11:919-28. 2010
    ..HBV/HCV coinfection is not uncommon with an estimated 7 - 20 million individuals affected worldwide. Patients with HBV/HCV coinfection have an increased risk for cirrhosis, hepatocellular carcinoma (HCC) and even death...
  97. ncbi request reprint The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection
    Andrej Potthoff
    Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany
    J Hepatol 49:688-94. 2008
    ..The efficacy of pegylated interferon alpha and ribavirin in HBV/HCV co-infected patients is unknown...
  98. ncbi request reprint Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation
    C Thomas Bock
    Department of Gastroenterology and Hepatology, Medical School of Hannover, FRG
    Gastroenterology 122:264-73. 2002
    ..However, we observed a severe clinical course of hepatitis B infection in several liver transplant recipients after the emergence of lamivudine resistance. This was associated with high viral load in the blood...
  99. doi request reprint Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk
    Tim O Lankisch
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Carl Neuberg Str 1, 30625 Hannover, Germany
    Cancer Epidemiol Biomarkers Prev 17:695-701. 2008
    ....
  100. doi request reprint Presumed cryptogenic liver disease in Germany: High prevalence of autoantibody-negative autoimmune hepatitis, low prevalence of NASH, no evidence for occult viral etiology
    S Heringlake
    Department of Gastroenterology, Ruhr University Bochum, Knappschaftskrankenhaus, Germany
    Z Gastroenterol 47:417-23. 2009
    ..Aim was to investigate possible underlying causes of presumed cryptogenic liver disease...
  101. doi request reprint Virological and clinical characteristics of delta hepatitis in Central Europe
    B Heidrich
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    J Viral Hepat 16:883-94. 2009
    ....